Gruticibart is under clinical development by Aronora and currently in Phase I for Thrombosis. According to GlobalData, Phase I drugs for Thrombosis have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Gruticibart’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Gruticibart overview

Gruticibart (AB-023) is under development for the treatment of cardiovascular disease, thrombosis, neurological disorders and end-stage renal disease. The drug candidate is administered through intravenous route. It is a recombinant monoclonal antibody that selectively targets assembly of the blood contact activation complex.

Aronora overview

Aronora operates in pharmaceutical and healthcare industry. It is headquartered in United States.

For a complete picture of Gruticibart’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.